NEOG vs NTLA
Neogen Corp. and Intellia Therapeutics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NEOG | NTLA |
|---|---|---|
| Revenue | $870.4M | $67.7M |
| Net income | $-7.9M | $-412.7M |
| Gross margin | 46.9% | — |
| Net margin | −0.9% | −609.9% |
| Return on equity | −0.4% | −53.5% |
| Diluted EPS | −$0.04 | −$3.81 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $31.9M | $-395.9M |
| Equity | $2.1B | $671.4M |
| Net debt / equity | 0.29× | — |
| Current ratio | 3.82× | 5.08× |
| Revenue CAGR 5y | 13.2% | 3.1% |
| Profit CAGR 5y | — | — |
NEOG bills 12.9× the revenue of NTLA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | NEOG | NTLA |
|---|---|---|
| FY2025 | $870.4M | $67.7M |
| FY2024 | $894.7M | $57.9M |
| FY2023 | $924.2M | $36.3M |
| FY2022 | $822.4M | $52.1M |
| FY2021 | $527.2M | $33.1M |
| FY2020 | $468.5M | $58.0M |
| FY2019 | $418.2M | $43.1M |
| FY2018 | $414.2M | $30.4M |
| FY2017 | $397.9M | $26.1M |
| FY2016 | $358.3M | $16.5M |
Net income by year
Bottom line
| Fiscal year | NEOG | NTLA |
|---|---|---|
| FY2025 | $-7.9M | $-412.7M |
| FY2024 | $-1.1B | $-519.0M |
| FY2023 | $-9.4M | $-481.2M |
| FY2022 | $-22.9M | $-474.2M |
| FY2021 | $48.3M | $-267.9M |
| FY2020 | $60.9M | $-134.2M |
| FY2019 | $59.5M | $-474.2M |
| FY2018 | $60.2M | $-85.3M |
| FY2017 | $63.1M | $-67.5M |
| FY2016 | $43.8M | $-31.6M |
More in this industry